Quality and learning management + Vendor management and governance = 2x stronger together

Audit Ready or Audit Scramble?

Vendor Oversight Gaps to Address Before an Inspection

Outsourcing clinical work to a CRO, central lab, or Interactive Response Technology (IRT) vendor does not outsource your regulatory obligations. Regulators treat vendors as extensions of the sponsor organization. In most inspection findings, the root cause is not a single underperforming vendor but fragmented oversight: qualification records, performance data, and quality agreements dispersed across systems that were never designed to connect. The following four gaps are worth closing before that question is asked.

1. The Project Plan Exists. Nobody Follows It.

Most CRO relationships begin well. A scope of work and a project plan are put in place, along with a quality agreement that assigns clear responsibility for deviations, investigations, and change control. The difficulty is that none of these documents are revisited afterward. The project plan sits in a folder. Small deviations accumulate. Scope quietly expands. By the time anyone notices, the distance between what was agreed and what is actually happening has widened enough for an auditor to walk straight through it.

Sound familiar? A CRO's quality agreement clearly assigns deviation and Corrective and Preventive Action (CAPA) responsibilities on paper. Six months into the study, a late safety report surfaces, and three separate people each assume someone else was tracking it.

Proactive Actions:

• Separate business (master services agreement) and quality responsibilities (quality agreement) into dedicated agreements, with named owners for deviations, investigations, safety communication, and change control.
  ‍
• Review, on a regular cadence, whether documented responsibilities still match actual practice.
  ‍
• Document and file a new agreement whenever the vendor's scope or personnel changes.

Key takeaway: A project plan nobody revisits is just a piece of paper.A review cadence is what catches drift before it becomes a finding.

2. Your Vendor Was Qualified Three Years Ago. That's It.

Vendor qualification tends to receive more attention during selection: a questionnaire is completed, an audit may take place, and then the file goes quiet. Three years later, the vendor's team has turned over, their quality system has evolved, the company may have been acquired, and the qualification file still reflects only the original assessment. Recent FDA warning letters have required companies to overhaul their supplier qualification programs, including the criteria used for selection, qualification, and disqualification. The message is unambiguous: qualifying a vendor once and moving on does not constitute a vendor management program.

Sound familiar? A CRO's lead bio statistician has left, data management has been subcontracted, and the vendor has received two GCP findings on another sponsor’s study none of which appear in the qualification file.

Proactive Actions:

• Establish a risk-based requalification cadence, triggered by personnel changes, ownership changes, quality events, subcontracting changes, or GCP findings.
  ‍
• Request and maintain qualification evidence, inspection records, and corrective actions on an annual basis.
  ‍
• Treat qualification as a living lifecycle rather than a point-in-time checkbox.

Key takeaway: If a vendor file cannot show what changed and what was done about it, it is not a file it is a snapshot. A snapshot in an insufficient proof of oversight.

3. Vendor Performance Only Comes Up When Something Breaks.

Vendor performance is often managed reactively. A late deliverable is escalated. A deviation triggers a call. Each issue is addressed individually, but no one steps back to examine the pattern across them. There is no consolidated view, no structured review forum, and no documented record of the decisions made about the relationship.

This is precisely where the quarterly business review earns its place: a recurring, structured conversation that brings quality, CAPAs, deviations, and operational performance into a single view. Without it, isolated problems get resolved while trends go undetected until an inspector asks for the evidence.

Sound familiar? Three late monitoring visit reports, two overdue CAPAs, and an unreported protocol deviation occur within a single quarter, each handled on its own. No dashboard shows the pattern. When an inspector asks how vendor performance is monitored, the process is described and then the inspector asks to see the records.

Proactive Actions:

• Define performance metrics aligned to each vendor's scope, including but not limited to visit report timeliness, query resolution, CAPA closure, and deviation rates. Review them on a cadence proportional to vendor criticality.
  ‍
• Use a consistent agenda covering quality and operations together, and document the decisions reached, not just the discussion.
  ‍
• Escalate recurring issues through the quality process, not only through the project team.‍

Key takeaway: When vendor performance only comes up once something breaks, that is theopposite of oversight.

4. Your Vendor Changed Something. You Found Out Late.

Vendors swap subcontractors, update SOPs, rotate project teams, and change systems. These changes can affect the quality of the work performed on a sponsor's behalf and the state of vendor qualification. A quality agreement may require notification, but without a defined process for how that notification happens, what triggers it, and how the sponsor assesses its impact, changes are absorbed without ever being evaluated for their effect on the study.

Sound familiar? A CRO switches its clinical trial management system (CTMS) platform mid-study and mentions the change in passing on a project call. It is never routed through change control. Three months later, an auditor asks about the system change, and there is no documented assessment, no approval, and no notification record.

Proactive Actions:

• Define change-notification responsibilities in the quality agreement across specific categories: personnel, systems, subcontractors, SOPs, and facilities.
  ‍
• Establish which changes require notification only, which require assessment, and which require approval before implementation.
  ‍
• Maintain a traceable record of what changed, when notification was received, and what was decided.‍

Key takeaway: A change that was never assessed is indistinguishable from a change thatwas never known about. Both look identical in an inspection.

The Common Thread

The root cause underlying all four gaps is the same: oversight evidence is fragmented, oversight responsibilities lack clear ownership and evidence of oversight is tracked inconsistently. A lean clinical operations team does not need more documents or more head count. It needs qualification, performance, agreement, change, audit, and CAPA records for each vendor consolidated into one traceable lifecycle available on demand, rather than reconstructed under pressure.

AuraGxP's AuraTrace platform brings vendor qualification, oversight, supplier lifecycle management, CAPA, deviation, change control, and document management into one connected system. If vendor oversight evidence is currently scattered in more locations than can be counted on one hand, that is the gap worth closing first.

‍

When a Full-Time Quality Hire is Too Early, But Compliance Risk is Not

Somewhere between “we just dosed our first patient” and “we’re building out a commercial quality organization,” most biotech startups pass through an uncomfortable middle stretch.
‍
There’s no clean rulebook, no headcount trigger, no line in a board deck that says “hire your VP of Quality now.”
‍
What there is, instead, is a slow accumulation of risk: undocumented deviations, informal vendor oversight, training records living in someone’s inbox, and a growing awareness that if an auditor or an FDA inspector walked in tomorrow, the story wouldn’t hold together.

This is the gap fractional QA support exists to close.

The Compliance Risk Doesn’t Wait for Your Hiring Plan

It’s tempting to treat Quality as a “later” problem something to build once there’s a commercial product, a bigger team, and a bigger budget.
‍
But regulatory exposure doesn’t wait for Series B. It starts the moment a clinical program, a manufacturing partner, or a lab process exists.

The numbers back this up:

• FDA’s broader FY2024 data shows that approximately one in five clinical investigator inspections and one in six sponsor/CRO inspections resulted in VAI or OAI classifications. The recurring findings, weak monitoring, protocol deviations, incomplete records, and safety-reporting gaps are precisely the risks that emerge when clinical activity and outsourcing grow faster than quality oversight. Fractional QA helps lean biotechs close that gap before it becomes an inspection or diligence issue.

• ClinicalTrials.gov surpassed 500,000 registered studies in 2024, a milestone reached 25 years after the registry launched with just over 1,000 studies. That scale reflects how the scale of clinical activity and therefore compliance surface area has grown industry-wide, even as inspection scrutiny holds steady.
  ‍
• In FDA GCP-focused inspections, some of the most frequently cited deficiencies involve failure to follow the monitoring schedule, inadequate investigator oversight, and gaps in trial records and documentation exactly the kind of oversight gaps that show up when no one owns quality as a full-time function.
  ‍
• Recruiting-industry data on Series A through C clinical-stage companies shows Director- and VP-level Clinical Operations hiring growing 31% year-over-year and VP Regulatory Affairs hiring growing 22%, reflecting increasing operational demands as companies progress through IND-enabling and early clinical development.

Put those together and the picture is clear: compliance obligations start as soon as clinical or GMP activity begins even if the Quality organization scales up later. Full Quality leadership, in most cases, does not arrive nearly that early.

Did You Know?

Only about 0.3% of FDA GCP inspections result in an Official Action Indicated(OAI) classification the tier warning letters come from.

But that doesn’t mean the other 99.7% are risk-free: most VAI-classified inspections still require a documented remediation response, and unaddressed findings compound over time.

Why a Full-Time Quality Hire is Often Premature

A senior QA hire is a significant, ongoing burn-rate commitment: salary, benefits, ramp time, and the organizational weight of standing up a function from scratch.
‍
For a company still validating its clinical or manufacturing strategy, that’s often capital better spent elsewhere. There’s also a structural mismatch.
‍
Early-stage programs don’t need a fully built QMS on day one they need the right amount of Quality infrastructure for where they actually are: enough to be inspection-ready and defensible, not so much that it becomes bureaucratic overhead the team can’t sustain.

‍
Bringing on a full-time quality leader before there’s a stable base of clinical or manufacturing activity to manage often means paying for capacity the organization isn’t yet positioned to use and QA professionals who join too early can find themselves without the infrastructure, budget, or organizational buy-in to do the job they were hired for.

Meanwhile, the risk of doing nothing compounds quietly: deviations pile up without a formal process, training records go untracked, vendor oversight is informal, and by the time a Phase 3 transition, an inspection, or a partnership diligence request arrives, the gaps are no longer small.

‍
Industry observers of Quality-system build-outs note that expanding a QMS after the fact tends to demand a disproportionate burst of process mapping, documentation, and retraining work that’s far cheaper to do incrementally from the start than to backfill under deadline pressure.

What Fractional QA Actually Solves

Fractional or embedded QA support gives a growing biotech access to senior quality expertise without the fixed cost, ramp time, or premature organizational build-out of a full-time hire.
‍
Instead of a single generalist, the company gets targeted expertise exactly where it’s needed, scaled up or down as the program matures.

In practice, this looks like:

• Quality System Design & Implementation - building a QMS that’s fit-for-purpose for your current phase, not a scaled-down version of a commercial-stage system you don’t need yet.
  ‍
• Deviation, CAPA & Change Control Management - the operational core of staying inspection-ready, run consistently even without in-house headcount.
  ‍‍
• Document Control & Records Management - so SOPs, batch records, and quality documentation live in one traceable, audit-ready system instead of scattered folders.
  ‍‍
• Audit Management & Inspection Readiness Support - so the first time your quality system is stress-tested isn’t the day an inspector walks in.
  ‍‍
• Supplier Qualification & Vendor Oversight - extending the same rigor to your CROs and CDMOs that you apply internally.
  ‍‍
• Training Program Design & GxP Training - ensuring role-based training is assigned, tracked, and defensible, not assumed.

This is the model behind AuraGxP’s approach to Quality Management & Learning: helping life sciences organizations build phase-appropriate Quality systems that scale with the company, rather than forcing a choice between “no quality function” and “premature full-time hire.”

What This Looks Like With AuraGxP

AuraGxP’s Quality and Learning services are built specifically around this middle stretch the point where compliance risk is real, but a full internal Quality department isn’t yet justified.
‍
Rather than dropping in a generic playbook, the engagement is scoped to your current stage: deviation management, CAPA, change control, audit management, and inspection readiness support delivered as ongoing, embedded services, backed by the AuraTrace™ Quality & Training Platform for centralized documentation, automated training assignments, role-based learning paths, and real-time compliance visibility.

That combination expert oversight plus a platform that makes the work traceable is what allows fractional support to hold up under an actual inspection, not just look good on paper.

Signals You’re Ready for This Conversation

You don’t need a fully built organization to start thinking about quality infrastructure. Some common triggers:

• You’re preparing for your first IND-enabling studies or first-in-human trial.
  ‍
• You’ve engaged (or are about to engage) your first CRO, CDMO, central laboratory, or other GxP vendor.
  ‍
• You’re not sure if your current documentation, oversight, or quality processes can withstand an audit or regulatory inspection.
  

• You’re preparing for investor due diligence, a licensing agreement, a merger or acquisition, or a strategic partnership where your Quality systems will be evaluated.
  ‍
• You’re implementing an electronic Quality Management System (eQMS), document management system, or learning management system and need someone who understands both quality and system implementation.
  ‍
• You’ve had informal signs of quality drift, inconsistent documentation, ad-hoc vendor communication, undocumented decisions, or missing training records and recognize that these small issues could become larger compliance risks as the company grows.
  ‍
• Training is inconsistent, difficult to track, or lacks documented evidence that employees have been trained on current procedures.
  ‍
• Deviations, CAPAs, change controls, or risk assessments are being handled inconsistently or not at all.

None of these require a full-time VP of Quality. All of them require someone accountable for Quality who knows what “inspection-ready” actually looks like.

Frequently Asked Questions

When should a biotech startup bring on fractional QA?
‍
Most companies benefit from starting before their first IND-enabling study, first CRO/CDMO engagement, or first outside diligence process not after a documentation gap has already surfaced.

Is fractional QA the same as hiring a consultant for a single project?
‍
Not quite. Fractional QA is ongoing and embedded covering deviation management, CAPA, training, and vendor oversight continuously rather than a fixed-scope project engagement.

Does fractional QA replace the need for a full-time quality hire eventually?
‍
Not necessarily. Fractional QA can bridge the gap before a full-time hire, complement an existing quality team, or provide specialized expertise as needs evolve. Even after an internal hire is made, fractional support can add execution capacity for a VP of Quality—or provide fractional leadership when the company’s budget currently supports only a junior quality hire.

The Bottom Line

The choice isn’t between “hire a quality leader” and “hope for the best.”

Fractional QA support exists precisely because compliance obligations start earlier than most organizations are staffed to handle them and because building a right-sized, phase-appropriate quality system now is far cheaper than remediating a gap later, whether that gap surfaces in an FDA inspection, a partner’s due diligence, or a deviation that should have been caught months earlier.

AuraGxP helps growing life sciences organizations build and scale exactly this kind of quality function inspection-ready from day one, without asking you to over-invest before you’re ready to do so.

If you’re weighing whether your compliance risk has outgrown your current quality resourcing, that’s a conversation worth having now, not after your next inspection.

Want to talk to AuraGxP about phase-appropriate QA support?
‍
Mail us at hello@auragxp.com

About the Author:

Diana I. Shea is a Quality Leader and consultant with over 20 years of experience in the pharmaceutical and biotechnology industries.  

She specializes in building and scaling phase-appropriate Quality Management Systems (QMS), GxP Quality programs, and inspection readiness initiatives for emerging and growth-stage organizations. Diana has led Quality Operations functions including Document Control, Training, and Quality Systems, while implementing compliant digital platforms that improve operational efficiency, inspection preparedness, and quality culture.  

GxP Supplier Qualification Basics for Biotechs

What growing teams need to know before an inspector asks‍

Why Supplier Qualification Matters ?

When manufacturing, testing, clinical operations, or other GxP-regulated activities are outsourced, accountability does not simply transfer to the service provider. CROs, CMOs, laboratories, and other critical suppliers operate as extensions of your quality system.

Regulators may therefore assess how effectively your organization selects, qualifies, contracts with, monitors, and periodically reviews these providers.

This is well-established across EU GMP Chapter 7, ICH Q10, and FDA enforcement under 21 CFR Part 211. The principle is consistent: the sponsor is accountable for demonstrating that outsourced activities are appropriately controlled.

A documented supplier qualification program is how you demonstrate that control when someone comes asking.

1. Risk-based qualification.
   ‍
   Not every vendor carries the same risk.
   ‍
   a. A CMO making your commercial product needs significantly more oversight than a translation service.
   
   b. Use a tiered framework that matches the level of assessment to the level of impact. High-risk vendors get audits and detailed quality agreements. Lower-risk vendors can be qualified through questionnaires and documentation.
   ‍
2. Clear quality agreements.
   ‍
   These define who owns what: deviations, CAPAs, change notifications, communication timelines, audit rights, and documentation responsibilities.
   ‍
   a. Quality agreements establish which party is responsible for specific activities, including deviations, investigations, CAPAs, change notifications, escalation timelines, audit rights, subcontracting, record retention, data access, and documentation.
   ‍
   b. EU GMP Chapter 7 calls for written contracts that clearly define the parties’ respective responsibilities and communication processes. FDA guidance similarly recommends quality agreements for defining and documenting CGMP-related manufacturing activities.
   ‍
   c. When responsibilities are unclear, important activities may be duplicated, delayed, or missed entirely.
   ‍‍
3. A centralized vendor registry.
   ‍
   ‍ Scattered qualification records (spreadsheets, email threads, and shared drives) are hard to maintain and harder to present during an inspection.
   ‍
   A centralized registry gives you visibility into qualification status, audit history, approval dates, and upcoming reviews in one place.
   ‍
4. ‍Ongoing performance monitoring.
   ‍
   ‍Qualification is not a one-time onboarding activity.
   ‍
   a. Supplier performance should be monitored throughout the relationship using indicators appropriate to the service and its associated risks. These may include delivery performance, deviation and CAPA trends, audit observations, recurring quality issues, responsiveness, change notifications, service-level performance, and financial exposure.
   ‍
   b. Ongoing monitoring enables organizations to identify deteriorating performance and emerging risks before they result in more serious quality, compliance, supply, or financial consequences.
   ‍
5. Documented vendor selection.
   ‍
   Be confident in why you chose a particular CRO or CMO based on true quality and business requirements, not word of mouth.
   ‍
   A preferred vendor list with standardized selection criteria saves time across programs and strengthens your position during inspections or due diligence.‍

Where Risks Tend to Creep In

‍In fast-growing biotechs, vendor networks expand faster than the processes around them.That is totally normal.

However, more often than not, qualification happens at onboarding but is not revisited on a regular cycle. Quality plans get signed and filed but are not actively maintained.
‍
Vendor oversight is minimally documented. Financial and Quality systems run independently, limiting visibility into vendor performance. Is attending recurring team meetings and paying invoices considered sufficient oversight?

The issue is not a lack of attention. Teams are focused on keeping trials running smoothly, coordinating with internal cross-functional stakeholders, and managing communications with vendors and sites to resolve issues as they arise.
‍
As a result, strategic vendor management often takes a back seat. The good news is that these challenges are addressable with the right processes, governance, and tools.

How AuraGxP Helps

AuraGxP helps life sciences organizations build supplier qualification and oversight programs that are structured, scalable, and inspection-ready.

Our services include:

• CRO and CMO selection support
• RFP development and management
• Risk-based supplier segmentation and qualification
• Quality agreement development
• Preferred-vendor program design
• Supplier performance monitoring
• Governance and periodic-review frameworks

AuraTrace™ connects these activities through a centralized vendor registry, qualification tracking, audit history, contract management, AI-assisted risk assessment, and integrated spend visibility.

By connecting quality, procurement, vendor oversight, and financial information, AuraGxP helps organizations turn fragmented supplier activities into a traceable and defensible operating model.

The goal is straightforward: make supplier qualification easier to manage, more consistent across functions, and more resilient as the organization grows—even when resources are limited or team members change.

Is your supplier program ready to withstand regulatory scrutiny?

Talk to AuraGxP.

Frequently Asked Questions

‍What is GxP supplier qualification?

It is the documented process of assessing, approving, and continuously monitoring vendors that perform GxP-regulated activities. It enables you to demonstrate effective oversight and inspection readiness throughout the vendor lifecycle.

How often should vendor qualification be reviewed?

High-risk vendors (CMOs, CROs) should be reassessed at least annually or when a triggering event occurs, such as a major deviation, audit finding, or scope change. Lower-risk vendors can follow a longer cycle.

Who is responsible for a deviation at a CMO or CRO?

Under EU GMP Chapter 7 and ICH Q10, the sponsor retains ultimate responsibility for ensuring outsourced activities are controlled, even though the vendor is responsible for the work itself.

Do small biotechs need a formal quality agreement with every vendor?

Let risk drive that decision. Vendors performing GxP-critical work (manufacturing, testing, clinical conduct) need a substantive quality agreement. Low-risk, non-GxP vendors typically do not require the same depth.
‍
Jaidyn Nguyen is Practice Leader – Procurement & Vendor Oversight at AuraGxP, where she leads procurement strategy, global partnerships, and vendor oversight initiatives designed to help biotech organizations scale with confidence.

The Hidden Growth Barrier in Biotech: Vendor Management

For more than two decades, I have worked across global CROs, pharmaceutical companies, and entrepreneurial ventures, building expertise in clinical operations, regulatory, quality, and digital transformation. As a pharmacy graduate with a master's degree in pharmacy practice, I've led global clinical studies, supported USFDA and EMA-backed marketing approvals, and co-founded a rapidly growing clinical research organization built on scalable systems and strong cross-functional governance.

‍Throughout that journey, I've worked with organizations at every stage of growth - from emerging biotechs to global enterprises. Despite their differences, I kept encountering the same challenges.

The Vendor Management Problem We Kept Trying to Patch‍

‍Having spent nearly twenty years in the biopharma industry, I watched organizations repeatedly address symptoms instead of solving root causes.

There was rarely a centralized system for vendor management activities or vendor performance management. Critical institutional knowledge often lived in inboxes, spreadsheets, or individual memories, making it difficult to preserve, share, and scale.

Vendor evaluations were frequently influenced by personal experiences rather than objective performance metrics. Decisions were shaped by who had a positive or negative interaction with a particular partner instead of a standardized, vendor evaluation framework that could be applied consistently across clinical development programs.

Most concerning, I repeatedly saw sponsor expectations and vendor capabilities drift out of alignment. The result was predictable: missed expectations, delayed timelines, increased costs, risk management challenges, and damaged relationships.

These weren't isolated operational issues. They were systemic challenges embedded within the industry's approach to vendor oversight, CRO management, and strategic partnerships.

And for too long, the solution was simply more tools, more services, and more complexity.

That is what drew me to AuraGxP.

A Foundation Built On The Right Belief

AuraGxP's vision starts with a simple but powerful principle: successful biotech companies are built on capable people and trusted partners.

Whether those resources come in the form of full-time employees (FTEs), functional service providers (FSPs), CROs, or strategic vendors, the foundation remains the same. Organizations perform best when they have the right people and the right partners supported by strong governance frameworks and effective vendor oversight.

AuraGxP helps companies establish that foundation, ensuring excellence from vendor selection through ongoing vendor management, performance oversight, and risk management.

That philosophy resonated deeply with me because it aligns with how I have always believed clinical operations should function. Quality and operational excellence are not outcomes that happen by chance. They are built intentionally from the start.

What Makes AuraGxP Different

What distinguishes AuraGxP from traditional consulting firms, software providers, or service organizations is that we are designed to enhance existing capabilities and not replace them.

Biotech companies shouldn't have to choose between working with industry-leading consultants, engaging a full-service CRO, or partnering with AuraGxP.

We support organizations wherever they need us.

In some cases, we oversee and execute an entire function. In others, we operate behind the scenes alongside clinical operations teams, providing governance, oversight, procurement strategy, and strategic support while existing partners continue delivering services.

Our approach is intentionally agnostic because our priority is helping clients achieve better outcomes—not forcing them into a particular ecosystem.

Bringing Consistency Through Every Stage Of Biotech Growth

Every biotech company is different.

They have unique cultures, operating models, development strategies, and growth trajectories.

What should remain constant, however, are the standards and values that guide decision-making.

My role is to help organizations maintain that consistency throughout every stage of growth. Scaling should not mean sacrificing quality. It should mean building systems and processes that preserve quality as complexity increases.

The barriers that slow growth are often operational rather than scientific. Fragmented vendor oversight. Subjective vendor evaluation processes. Loss of institutional knowledge. Limited visibility into vendor performance, compliance, and risk.

These are all solvable challenges when approached methodically.

The Impact AuraGxP Can Have On Life Science Organizations

My vision for AuraGxP is straightforward.

I want biotech companies to have access to an objective, structured approach to vendor management, supported by meaningful insights that strengthen decision-making at every level.

That means creating:

• standardized vendor evaluation frameworks
• robust vendor performance management and oversight
• clear governance frameworks and accountability structures
• actionable operational insights
• greater transparency across vendor relationships
• stronger risk management processes
• more effective supplier relationship management

For emerging and growing biotech companies, these capabilities are often viewed as something to implement later.

I believe they should be established early.

Strong vendor management infrastructure is one of the highest-leverage investments an organization can make because it affects quality, timelines, resource allocation, clinical trial operations, and ultimately program success.

Why Better Vendor Oversight Matters

At its core, better vendor management is not simply an operational improvement.

It is how clinical trials stay on track.

It is how organizations allocate resources effectively.

It is how teams identify risks before they become problems.

It is how strategic partnerships create long-term value.

And ultimately, it is how companies make decisions that put patients first.

That is why I joined AuraGxP.

It is exactly why I believe AuraGxP is uniquely positioned to help biotech companies build scalable, objective, and flexible vendor management programs that support growth without compromising quality, operational excellence, or patient outcomes.

Jaidyn Nguyen is Practice Leader – Procurement & Vendor Oversight at AuraGxP, where she leads procurement strategy, global partnerships, and vendor oversight initiatives designed to help biotech organizations scale with confidence.

‍

‍The Challenge: Quality That Can't Keep Pace with Growth

Throughout my career in the life sciences industry, I've seen many biotech companies encounter the same challenge. They have innovative science, strong leadership, and tremendous potential — but as they move from research and development into clinical trials and commercialization, their Quality infrastructure often struggles to keep pace.

Disconnected processes, manual and paper-based activities, inconsistent documentation practices, and a compliance-focused mindset can create significant bottlenecks that slow growth and increase regulatory risk. Standard Operating Procedures (SOPs) go unreviewed. CAPA (Corrective and Preventive Action) programs sit dormant until an auditor surfaces a finding. Change control processes become reactive rather than proactive.

Too often, Quality is viewed as a regulatory requirement rather than a strategic business function that enables growth and operational excellence.

These recurring challenges reinforced my belief that the industry needs a fundamentally different approach — one that treats Quality as a business enabler, not simply a compliance obligation.

Why AuraGxP Stood Out

That perspective is exactly what drew me to AuraGxP.

AuraGxP was founded on the idea that Quality should accelerate growth, not hinder it. Unlike traditional consulting firms that deliver recommendations and leave implementation to the client, or software vendors that offer technology without the necessary GxP expertise, AuraGxP combines deep industry knowledge with practical, hands-on execution.

AuraGxP’s Quality-as-a-Service model helps organizations build scalable, fit-for-purpose Quality Systems that support regulatory compliance, operational efficiency, and long-term growth; without asking companies to choose between expertise and execution.

Turning Quality into a Competitive Advantage

My focus has always been helping organizations establish and mature the systems that protect both patients and programs. That means building robust Quality Management Systems, strengthening inspection readiness, improving supplier qualification and oversight, streamlining audit management, and developing sustainable compliance programs that scale with the business.

That work touches every layer of an organization. It means implementing risk-based quality planning that prioritizes resources where they matter most, and building deviation management and root cause analysis programs that drive real corrective action — not just documentation. It means establishing GCP, GMP, and GLP compliance frameworks aligned with FDA, EMA, and ICH guidelines, and putting vendor qualification and third-party audit programs in place that ensure supply chain integrity. And it means investing in training and quality culture so that compliance becomes part of how a team operates every day, not something that gets bolted on before an inspection. Increasingly, it also means guiding organizations through the transition to Electronic Quality Management Systems that replace fragmented, paper-based workflows with scalable, audit-ready infrastructure.

By integrating these Quality principles early — and designing systems that evolve alongside the organization — companies can avoid the costly rework, inefficiencies, and compliance gaps that typically surface during critical growth stages such as funding rounds, regulatory inspections, clinical advancement, technology transfer, or commercialization.

When Quality is built intentionally from the start, it becomes a competitive advantage rather than a constraint.

More Than Consultants — A True Partner

What makes AuraGxP different is our partnership approach. We don't simply identify gaps and hand over a report. We help clients close them.

We work as an extension of our clients' teams, providing practical solutions that align Quality, compliance, and business objectives. Our audit services reflect this philosophy directly. Rather than treating audits as retrospective compliance exercises, we use them as strategic tools to identify risk, drive continuous improvement, and strengthen Quality Systems before issues become obstacles — whether that means an internal audit, a vendor audit, or full pre-inspection readiness support.

This proactive, risk-based approach helps organizations make better decisions, reduce regulatory exposure, and maximize limited resources.For lean biotech teams especially,that kind of embedded expertise is the difference between staying ahead of regulators and scrambling to respond to them.

Building the Future of Quality

My vision for AuraGxP is to help redefine how emerging biotech companies think about Quality — not as a function that exists to satisfy regulatory bodies like the FDA or EMA, but as a strategic foundation that makes everything else possible.

By providing scalable, technology-enabled, and risk-based quality management solutions, we help organizations establish strong foundations early, freeing their teams to focus on what matters most: advancing innovative therapies and products that improve patients' lives.

The most successful biotech companies of the future will be those that integrate Quality into their business strategy from the beginning — with the right systems, the right partners, and the right culture of quality and compliance embedded at every level.

AuraGxP is uniquely positioned to help make that vision a reality.

Diana I. Shea is a Quality Leader and consultant with over 20 years of experience in the pharmaceutical and biotechnology industries.  

She specializes in building and scaling phase-appropriate Quality Management Systems (QMS), GxP Quality programs, and inspection readiness initiatives for emerging and growth-stage organizations. Diana has led Quality Operations functions including Document Control, Training, and Quality Systems, while implementing compliant digital platforms that improve operational efficiency, inspection preparedness, and quality culture.  

Her expertise includes developing sustainable quality frameworks that support innovation while maintaining regulatory compliance across GxP environments. She holds a Master of Science in Management, complementing her strategic leadership and operational expertise. Diana is driven by a strong commitment to patient safety, continuous improvement, and advancing innovative therapies through practical, effective, and scalable quality practices.

‍

‍

‍

‍

‍

Having spent more than two decades working with biotech companies—from early-stage startups to successful exits—I noticed a common challenge that had very little to do with science.

Most biotech leaders are experts in developing therapies, advancing clinical programs, and creating value for patients. Yet as companies grow, they are suddenly expected to manage an increasingly complex ecosystem of vendors, consultants, CROs, quality systems, budgets, contracts, and quality requirements.

I've seen companies succeed because they built the right operational foundation early. I've also seen promising programs struggle because leadership teams were overwhelmed by disconnected processes, limited visibility, and a lack of experienced operational support.

The reality is that many emerging biotech companies don't just need software. They need guidance, expertise, and trusted partners who understand the challenges of scaling a regulated business.

That realization inspired AuraGxP.

We built AuraGxP around three integrated pillars:

Consulting to help companies design scalable operating models, strengthen governance, and make better strategic decisions.

Software to bring Quality, Procurement, Vendor Oversight, and Spend into a connected platform that provides visibility, traceability, and control.

Managed Services to provide hands-on operational support so lean teams can focus on advancing their science while we help manage the complexity behind the scenes.

Our vision is simple: to become the trusted operational partner for growing biotech companies.

Whether a company is preparing for its first clinical trial, managing a growing network of vendors, preparing for due diligence, or scaling toward commercialization, we believe they deserve more than a collection of disconnected tools and service providers.

They deserve a partner that can advise, enable, and support them every step of the journey.

At AuraGxP, we are combining industry expertise, technology, and white-glove services to help biotech innovators build stronger, more scalable organizations—so they can spend less time managing operations and more time delivering breakthroughs for patients.

Because great science deserves great execution